X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES SHASUN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES SHASUN LTD CIPLA/
STRIDES SHASUN LTD
 
P/E (TTM) x 40.5 43.4 93.4% View Chart
P/BV x 3.7 1.1 345.6% View Chart
Dividend Yield % 0.5 0.9 49.5%  

Financials

 CIPLA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    CIPLA
Mar-18
STRIDES SHASUN LTD
Mar-17
CIPLA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs6631,275 52.0%   
Low Rs479918 52.2%   
Sales per share (Unadj.) Rs189.0389.6 48.5%  
Earnings per share (Unadj.) Rs17.628.0 62.9%  
Cash flow per share (Unadj.) Rs34.048.9 69.6%  
Dividends per share (Unadj.) Rs3.004.50 66.7%  
Dividend yield (eoy) %0.50.4 128.0%  
Book value per share (Unadj.) Rs176.7303.1 58.3%  
Shares outstanding (eoy) m805.1289.42 900.4%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.8 107.3%   
Avg P/E ratio x32.539.2 82.8%  
P/CF ratio (eoy) x16.822.4 74.8%  
Price / Book Value ratio x3.23.6 89.3%  
Dividend payout %17.116.1 106.0%   
Avg Mkt Cap Rs m459,72498,036 468.9%   
No. of employees `00023.65.8 407.1%   
Total wages/salary Rs m26,9015,881 457.4%   
Avg. sales/employee Rs Th6,446.16,005.9 107.3%   
Avg. wages/employee Rs Th1,139.41,014.0 112.4%   
Avg. net profit/employee Rs Th600.0431.2 139.1%   
INCOME DATA
Net Sales Rs m152,19334,834 436.9%  
Other income Rs m3,5771,686 212.2%   
Total revenues Rs m155,76936,520 426.5%   
Gross profit Rs m28,2646,428 439.7%  
Depreciation Rs m13,2281,872 706.8%   
Interest Rs m1,1422,269 50.3%   
Profit before tax Rs m17,4703,973 439.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-284 -772.2%   
Extraordinary Inc (Exp) Rs m-775-1,006 77.1%   
Tax Rs m2,501470 532.1%   
Profit after tax Rs m14,1662,501 566.4%  
Gross profit margin %18.618.5 100.6%  
Effective tax rate %14.311.8 121.0%   
Net profit margin %9.37.2 129.6%  
BALANCE SHEET DATA
Current assets Rs m108,14138,165 283.4%   
Current liabilities Rs m38,32230,402 126.1%   
Net working cap to sales %45.922.3 205.8%  
Current ratio x2.81.3 224.8%  
Inventory Days Days9777 125.4%  
Debtors Days Days74104 71.2%  
Net fixed assets Rs m109,41137,639 290.7%   
Share capital Rs m1,610894 180.1%   
"Free" reserves Rs m140,68226,210 536.7%   
Net worth Rs m142,29227,105 525.0%   
Long term debt Rs m36,62116,377 223.6%   
Total assets Rs m228,60681,168 281.6%  
Interest coverage x16.32.8 592.3%   
Debt to equity ratio x0.30.6 42.6%  
Sales to assets ratio x0.70.4 155.1%   
Return on assets %6.75.9 113.9%  
Return on equity %10.09.2 107.9%  
Return on capital %10.012.1 82.6%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69113,465 383.9%   
Fx outflow Rs m21,0334,076 516.1%   
Net fx Rs m30,6589,389 326.5%   
CASH FLOW
From Operations Rs m14,6282,881 507.7%  
From Investments Rs m-8,540-7,051 121.1%  
From Financial Activity Rs m-3,8553,382 -114.0%  
Net Cashflow Rs m2,431-788 -308.7%  

Share Holding

Indian Promoters % 16.0 27.7 57.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 37.8 32.3%  
FIIs % 23.7 8.6 275.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.9 101.2%  
Shareholders   161,166 56,241 286.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare CIPLA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 19, 2018 (Close)

TRACK CIPLA

CIPLA - UNICHEM LAB COMPARISON

COMPARE CIPLA WITH

MARKET STATS